KIYATEC Announces Investment from Seae Ventures and Names Co-founder and Managing Partner Jason Robart to its Board of Directors
01 May, 2021
– Mablink Bioscience is a Lyon, France-based company developing antibody-drug conjugates (ADC).
– The company raised €4M in a seed financing round.
– Elaia Partners led the round with participation from Pertinence Invest 2 (Sofimac Innovation advised by Mérieux Equity Partners), Sham Innovation Santé (advised by Turenne Capital), Fondation Fournier-Majoie, Simba Santé (Angelor) and Crédit Agricole Création.
– The new investment will be used to move forward its ADC pipeline.